JNJJohnson & Johnson
# 60 · $263.81 (-1.42%) · $635.07B · Healthcare
Rango 52 semanas
Datos de mercado
- P/E
- 40.03
- 1M
- -2.54%
- 1A
- +40.15%
- Rentab.
- 2.00%
- RSI
- 58.97
- MACD
- +0.42%
Desglose
Por qué
- PEG of 0.44
- earnings growth of 90.6%
- ROE of 24.8%
- profit margin of 21.5%
- 12-1 momentum return of 43.8%
- trading 8.2% above 200d SMA
- MACD histogram positive
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
3
3 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Altman Z in grey zoneMedia
Z-Score 2.87 (1.81–2.99) — not clearly safe
- Earnings quality (accruals)Media
operating cash flow below reported net income — profits not backed by cash
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Rising leverageInfo
debt/assets higher than the previous fiscal year
- Segment revenue concentrationInfo
64% of revenue from the Innovative Medicine segment
Análisis de la empresa
Business Overview Johnson & Johnson (JNJ) is a diversified healthcare company focused on Innovative Medicine (pharmaceuticals) and MedTech (medical devices & technology), generating revenue primarily from prescription medicine sales and medical device sales to healthcare providers and payors globally. Its portfolio spans major therapeutic areas (e.g., Immunology, Oncology, Neuroscience) and device categories (e.g., cardiovascular, surgery, vision, orthopaedics). Market Position JNJ is one of the world’s largest healthcare companies with broad scale across pharma and devices; competitive differentiation is driven by R&D, global commercial infrastructure, and a diversified portfolio across multiple disease areas and procedure categories. Demand is heavily influenced by reimbursement/third‑party payors and healthcare system pricing dynamics, particularly in the U.S. Key Segments JNJ reports two operating segments: Innovative Medicine and MedTech; in fiscal 2024, segment sales were approximately $57.0B (Innovative Medicine) and $31.9B (MedTech).
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31